Rockingstone Advisors LLC Lowers Position in iShares Biotechnology ETF (NASDAQ:IBB)

Rockingstone Advisors LLC lowered its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 26.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,063 shares of the financial services provider’s stock after selling 2,217 shares during the period. Rockingstone Advisors LLC’s holdings in iShares Biotechnology ETF were worth $802,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in IBB. Darwin Wealth Management LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth $29,000. Highline Wealth Partners LLC acquired a new stake in iShares Biotechnology ETF during the third quarter worth about $30,000. Ashton Thomas Securities LLC acquired a new stake in iShares Biotechnology ETF during the third quarter worth about $36,000. Modus Advisors LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter worth about $41,000. Finally, Voisard Asset Management Group Inc. acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

IBB opened at $133.42 on Thursday. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The firm has a 50 day moving average price of $137.51 and a 200 day moving average price of $141.93.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.